Florian Then Bergh

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

Sven Jarius, Klemens Ruprecht, Brigitte Wildemann et al. · Journal of Neuroinflammation · 2012 · 764 citations · Full text

Life Sciences, Immunology, Neurology +9

Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies

Carsten Finke, J. Heine, Sigrid Reuter et al. · JAMA Neurology · 2017 · 313 citations · Full text

Life Sciences, Neurology, Neuroscience +16

Multiple sclerosis: Comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

Oliver Neuhaus, Cinthia Farina, Alexander Yassouridis et al. · Proceedings of the National Academy of Sciences · 2000 · 302 citations

Life Sciences, Immunology, Pathobiology +17

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Ivo N. van Schaik, Vera Bril, Nan van Geloven et al. · The Lancet Neurology · 2017 · 269 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +11